ABL1 and leukemia: Combining HDACis with imatinib in resistant leukemia cells greatly increases mitochondrial damage and cell death, potentially because it prevents the acetylated heat shock protein 90 from binding to BCR-ABL, aiding in the proteasomal degradation of BCR-ABL protein [127, 128].